These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1133 related articles for article (PubMed ID: 21193853)
21. A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. Edwards FA Trends Neurosci; 2019 May; 42(5):310-322. PubMed ID: 31006494 [TBL] [Abstract][Full Text] [Related]
22. Tau aggregation and its interplay with amyloid-β. Nisbet RM; Polanco JC; Ittner LM; Götz J Acta Neuropathol; 2015 Feb; 129(2):207-20. PubMed ID: 25492702 [TBL] [Abstract][Full Text] [Related]
23. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. Pereira JB; Janelidze S; Ossenkoppele R; Kvartsberg H; Brinkmalm A; Mattsson-Carlgren N; Stomrud E; Smith R; Zetterberg H; Blennow K; Hansson O Brain; 2021 Feb; 144(1):310-324. PubMed ID: 33279949 [TBL] [Abstract][Full Text] [Related]
24. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Mandelkow EM; Stamer K; Vogel R; Thies E; Mandelkow E Neurobiol Aging; 2003 Dec; 24(8):1079-85. PubMed ID: 14643379 [TBL] [Abstract][Full Text] [Related]
25. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease. Madav Y; Wairkar S; Prabhakar B Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016 [TBL] [Abstract][Full Text] [Related]
27. Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. Rajmohan R; Reddy PH J Alzheimers Dis; 2017; 57(4):975-999. PubMed ID: 27567878 [TBL] [Abstract][Full Text] [Related]
28. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. Majdi A; Sadigh-Eteghad S; Rahigh Aghsan S; Farajdokht F; Vatandoust SM; Namvaran A; Mahmoudi J Rev Neurosci; 2020 May; 31(4):391-413. PubMed ID: 32017704 [TBL] [Abstract][Full Text] [Related]
29. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport. Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715 [TBL] [Abstract][Full Text] [Related]
30. Pathophysiological mechanism and natural preventive and therapeutic strategies of Alzheimer's disease. Basli A; Bounaas J Nutr Health; 2023 Sep; 29(3):403-413. PubMed ID: 36377316 [TBL] [Abstract][Full Text] [Related]
31. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647 [TBL] [Abstract][Full Text] [Related]
32. Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Trojanowski JQ; Shin RW; Schmidt ML; Lee VM Neurobiol Aging; 1995; 16(3):335-40; discussion 341-5. PubMed ID: 7566343 [No Abstract] [Full Text] [Related]
33. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein. Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210 [TBL] [Abstract][Full Text] [Related]
34. Spreading of Pathology in Alzheimer's Disease. Lv ZY; Tan CC; Yu JT; Tan L Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460 [TBL] [Abstract][Full Text] [Related]
35. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography. Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076 [TBL] [Abstract][Full Text] [Related]
36. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Ittner LM; Ke YD; Delerue F; Bi M; Gladbach A; van Eersel J; Wölfing H; Chieng BC; Christie MJ; Napier IA; Eckert A; Staufenbiel M; Hardeman E; Götz J Cell; 2010 Aug; 142(3):387-97. PubMed ID: 20655099 [TBL] [Abstract][Full Text] [Related]
37. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease. Shin J Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001 [No Abstract] [Full Text] [Related]
38. Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses. Takahashi RH; Capetillo-Zarate E; Lin MT; Milner TA; Gouras GK Neurobiol Aging; 2010 Jul; 31(7):1145-52. PubMed ID: 18771816 [TBL] [Abstract][Full Text] [Related]
39. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Mukaetova-Ladinska EB; Garcia-Siera F; Hurt J; Gertz HJ; Xuereb JH; Hills R; Brayne C; Huppert FA; Paykel ES; McGee M; Jakes R; Honer WG; Harrington CR; Wischik CM Am J Pathol; 2000 Aug; 157(2):623-36. PubMed ID: 10934165 [TBL] [Abstract][Full Text] [Related]
40. [Expression of tau-related protein in spinal cord of patients with Alzheimer's disease]. GUO YJ; WANG LN; ZHU MW; ZHANG HH; HU YZ; HAN ZT; LI JM; WANG DX Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):161-4. PubMed ID: 21575385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]